The risk of having a healthcare-associated infection was 16% lower in 2015 than in 2011.
The CHEST Expert Cough Panel agreed on cough, dyspnea, pleural pain, sweating, shivers, aches, temperature of ≥38°C, tachypnea, and new and localizing chest examination signs as clinical symptoms as criteria suggestive of pneumonia in outpatient adults.
Survey finds variance in provider knowledge of adult pneumococcal vaccine recommendations.
Significant associations were seen between increased average prenatal carbon monoxide and reduced time to peak tidal expiratory flow to expiratory time, increased respiratory rate, and increased minute ventilation.
Antipseudomonal combination therapy has shown poorer efficacy than antipseudomonal monotherapy in individuals with suspected pseudomonal pneumonia.
The burden of childhood and infant pneumonia can be effectively reduced through the use of the pneumococcal Haemophilus influenzae protein D conjugate vaccine.
PCV13 in adults age <65 years with diabetes could reduce a substantial number of pneumonia hospitalizations.
The use of fluoroquinolones in stable patients with community-acquired pneumonia can be reduced with stewardship programs that share antibiotic use data and provide guidance for step-down therapy.
The FDA has approved Nuzyra for the treatment of adult patients with CABP and acute bacterial skin and skin structure infections.
For patients with CAP, antibiotic regimens including a fluoroquinolone may reduce mortality risk by 1-2% compared to beta-lactams and cephalosporins alone.
Previous antibiotic use and mechanical invasive ventilation were risk factors for multidrug-resistant pathogens in hospital-associated or ventilator-associated pneumonia.
Patients with community-acquired pneumonia who received corticosteroids had a lower incidence of myocardial infarction compared with those who did not.
The Breakthrough designation follows an FDA examination of results from a Phase 2 randomized, double-blind trial which evaluated the safety and immunogenicity of the treatment in adults aged 60 to 64 years.
The full findings from the study will be presented at a future scientific conference; Merck plans to include the data in a supplemental New Drug Application for Zerbaxa which will be submitted to the Food and Drug Administration.
Corticosteroids should not be used concomitantly with antiviral therapy in patients with influenza pneumonia.
Influenza proved to be an independent risk factor for invasive pulmonary aspergillosis.
The clinical prediction tool that uses confusion, uremia, elevated respiratory rate, and hypotension in community-acquired pneumonia demonstrated an association with ICU admittance.
An algorithm based on risk factors for resistant pathogens and illness severity can simplify pneumonia treatment, improve the accuracy of empiric therapy, reduce mortality, and help avoid overusing broad spectrum therapy in some patients.
Rate of incident pneumonia increased in second year after initiating treatment with proton pump inhibitors.
Coal workers' pneumoconiosis deaths significantly decreased from 1999 to 2016 for residents ≥25 years.
An investigation into an outbreak of NDM-producing Klebsiella pneumoniae across 2 Belgian hospitals identified an outpatient clinic as the likely common site of transfer and highlights the importance of infection control measures in outpatient settings.
The Committee's recommendation was based on data from the omadacycline global development program that included nearly 2000 adults in three Phase 3 studies.
Inappropriate antibiotic prescriptions were highest among urgent care facilities (45.7%), with emergency departments (24.6%), medical offices (17.0%), and retail clinics (14.4%) following.
Most children who died of pneumococcus and Haemophilus influenzae type b presented with pneumonia.
Advanced diagnostic platforms to identify viruses can help patients with severe lower respiratory tract infections avoid unnecessary diagnostic testing, reduce antibiotic use, and initiate antiviral therapy.
To investigate what impact antibiotic treatment duration has on CAP outcomes, researchers from the Warren Alpert Medical School of Brown University conducted a search of various databases for studies comparing the safety and efficacy of treatment regimens lasting ≤6 days (short) and ≥7 days (long).
Investigators examined the incidence and outcomes of pneumonia in patients with acute ischemic stroke and type 2 diabetes.
Most deaths related to community-acquired pneumonia that occurred at tertiary-case hospitals were not preventable.
The real-world effectiveness of PCV13 vaccine in preventing hospitalization for vaccine-type community-acquired pneumonia was assessed.
Although clinical presentation was similar in both community-acquired pneumonia and non-pneumonia exacerbations, CRP, glucose, and leukocytes were higher in the former vs the latter.